Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Mol Genet Metab ; 131(1-2): 90-97, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32928639

RESUMEN

BACKGROUND: The plasma acylcarnitine profile is frequently used as a biochemical assessment for follow-up in diagnosed patients with fatty acid oxidation disorders (FAODs). Disease specific acylcarnitine species are elevated during metabolic decompensation but there is clinical and biochemical heterogeneity among patients and limited data on the utility of an acylcarnitine profile for routine clinical monitoring. METHODS: We evaluated plasma acylcarnitine profiles from 30 diagnosed patients with long-chain FAODs (carnitine palmitoyltransferase-2 (CPT2), very long-chain acyl-CoA dehydrogenase (VLCAD), and long-chain 3-hydroxy acyl-CoA dehydrogenase or mitochondrial trifunctional protein (LCHAD/TFP) deficiencies) collected after an overnight fast, after feeding a controlled low-fat diet, and before and after moderate exercise. Our purpose was to describe the variability in this biomarker and how various physiologic states effect the acylcarnitine concentrations in circulation. RESULTS: Disease specific acylcarnitine species were higher after an overnight fast and decreased by approximately 60% two hours after a controlled breakfast meal. Moderate-intensity exercise increased the acylcarnitine species but it varied by diagnosis. When analyzed for a genotype/phenotype correlation, the presence of the common LCHADD mutation (c.1528G > C) was associated with higher levels of 3-hydroxyacylcarnitines than in patients with other mutations. CONCLUSIONS: We found that feeding consistently suppressed and that moderate intensity exercise increased disease specific acylcarnitine species, but the response to exercise was highly variable across subjects and diagnoses. The clinical utility of routine plasma acylcarnitine analysis for outpatient treatment monitoring remains questionable; however, if acylcarnitine profiles are measured in the clinical setting, standardized procedures are required for sample collection to be of value.


Asunto(s)
Cardiomiopatías/sangre , Carnitina O-Palmitoiltransferasa/deficiencia , Carnitina/análogos & derivados , Síndromes Congénitos de Insuficiencia de la Médula Ósea/sangre , Errores Innatos del Metabolismo Lipídico/sangre , Errores Innatos del Metabolismo/sangre , Enfermedades Mitocondriales/sangre , Miopatías Mitocondriales/sangre , Proteína Trifuncional Mitocondrial/deficiencia , Enfermedades Musculares/sangre , Enfermedades del Sistema Nervioso/sangre , Rabdomiólisis/sangre , 3-Hidroxiacil-CoA Deshidrogenasas/genética , 3-Hidroxiacil-CoA Deshidrogenasas/metabolismo , Acetil-CoA C-Aciltransferasa/genética , Acetil-CoA C-Aciltransferasa/metabolismo , Acil-CoA Deshidrogenasa de Cadena Larga/sangre , Isomerasas de Doble Vínculo Carbono-Carbono/genética , Isomerasas de Doble Vínculo Carbono-Carbono/metabolismo , Cardiomiopatías/dietoterapia , Cardiomiopatías/patología , Cardiomiopatías/terapia , Carnitina/sangre , Carnitina/genética , Carnitina/metabolismo , Carnitina O-Palmitoiltransferasa/sangre , Síndromes Congénitos de Insuficiencia de la Médula Ósea/dietoterapia , Síndromes Congénitos de Insuficiencia de la Médula Ósea/patología , Síndromes Congénitos de Insuficiencia de la Médula Ósea/terapia , Enoil-CoA Hidratasa/genética , Enoil-CoA Hidratasa/metabolismo , Terapia por Ejercicio , Ayuno , Femenino , Humanos , Errores Innatos del Metabolismo Lipídico/dietoterapia , Errores Innatos del Metabolismo Lipídico/patología , Errores Innatos del Metabolismo Lipídico/terapia , 3-Hidroxiacil-CoA Deshidrogenasa de Cadena Larga/sangre , Masculino , Errores Innatos del Metabolismo/dietoterapia , Errores Innatos del Metabolismo/patología , Errores Innatos del Metabolismo/terapia , Enfermedades Mitocondriales/dietoterapia , Enfermedades Mitocondriales/patología , Enfermedades Mitocondriales/terapia , Miopatías Mitocondriales/dietoterapia , Miopatías Mitocondriales/patología , Miopatías Mitocondriales/terapia , Proteína Trifuncional Mitocondrial/sangre , Enfermedades Musculares/dietoterapia , Enfermedades Musculares/patología , Enfermedades Musculares/terapia , Enfermedades del Sistema Nervioso/dietoterapia , Enfermedades del Sistema Nervioso/patología , Enfermedades del Sistema Nervioso/terapia , Racemasas y Epimerasas/genética , Racemasas y Epimerasas/metabolismo , Rabdomiólisis/dietoterapia , Rabdomiólisis/patología , Rabdomiólisis/terapia
2.
Mol Genet Metab Rep ; 24: 100632, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32793418

RESUMEN

INTRODUCTION: Mitochondrial fatty acid oxidation disorders (FAODs) are a heterogeneous group of hereditary autosomal recessive diseases included in newborn screening (NBS) program in Italy. The aim of this study was to analyse FAODs cases, identified either clinically or by NBS,for clinical and genetic characterization and to evaluate a five years' experience of NBS, in the attempt to figure out the complexity of genotype-phenotype correlation and to confirm the clinical impact of NBS in our centre experience. MATERIALS AND METHODS: We analysed FAODs patients diagnosed either by NBS or clinically, followed since February 2014 to April 2019 at the Regional Screening Centre and Inherited Metabolic Diseases Unit of Verona. Diagnosis was confirmed by plasma acylcarnitines, urinary organic acids, enzymatic and genetic testing. For not clear genotypes due to the presence of variants of uncertain significance, in silico predictive tools have been used as well as enzymatic activity assays. Patients underwent clinical, nutritional and biochemical follow up. RESULTS: We diagnosed 30 patients with FAODs. 20 by NBS: 3 CUD, 6 SCADD, 5 MCADD, 4 VLCADD, 2 MADD. Overall incidence of FAODs diagnosed by NBS was 1:4316 newborns. No one reported complications during the follow up period. 10 patients were diagnosed clinically: 2 CUD, 2 CPT2D, 1 VLCADD, 5 MADD. Mean age at diagnosis was 29.3 years. Within this group, complications or symptoms were reported at diagnosis, but not during follow-up. 12 mutations not previously reported in literature were found, all predicted as pathogenic or likely pathogenic. DISCUSSION AND CONCLUSIONS: Our study highlighted the great phenotypic variability and molecular heterogeneity of FAODs and confirmed the importance of a tailored follow up and treatment. Despite the short duration of follow up, early identification by NBS prevented diseases related complications and resulted in normal growth and psycho-motor development as well.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA